- Maximizing
profit by creating, leveraging products with 10-to-20x profitability
margins
- Investors
encouraged to review CBD Biotech’s impressive product line, strategic plan
for revenue increase.
- Driving
growth in new year with growing demand for CBD products
ChineseInvestors.com Inc. (OTCQB: CIIX) is a leading
financial-information website for Chinese-speaking investors in the United
States and China. CIIX CEO Warren Wang recently discussed the company’s goals
and bright outlook for 2020 during a MoneyTV.net interview with Donald
Baillargeon (http://ibn.fm/PlWY7).
The new year looks promising for CIIX, Wang stated. Using
Chinese language character sets, the company offers investor-education products
and services, real-time market commentary, analysis and educational-related
services as well as advertising, public-relations-related support services and
consultative services to smaller private companies.
In addition to financial services, the company has invested
in the growing demand for cannabidiol (CBD)-based nutrition and health
products. An IPO of CIIX’s wholly owned foreign enterprise, CBD Biotech, is
anticipated early this year (http://ibn.fm/q0Ycx).
In his interview, Wang gave an overview of CBD Biotech’s impressive product
line, and he urged investors to do likewise in order to grasp the company’s
plan to achieve profitability.
CBD Biotech’s major asset is its 40,000 repeat customers,
said Wang, who discussed a B2C division of the company whose purpose is to
target these consumers through telemarking and social media. The goal is to see
how to retain this targeted group and keep these customers coming back. In
addition, a separate CBD Biotech B2B division is working to maximize revenue to
wholesalers. The two divisions have the same goals: increase sales, lower costs
and maximize profitability.
Regarding stock price, Wang pointed out the hard work of
employees, the company’s revenue, and the quality of the product line and
profit margins as he shared with investors his confidence in the future of
CIIX. CBD cosmetics products have a 10-to-20x profit margin, Wang noted, as he
explained that the CBD cosmetic product line will be a vital part of driving
growth as the company works to lower costs and maximize profitability. The
company achieved almost $5 million in revenue during calendar year 2019, Wang
said, and he expressed his optimism regarding the upcoming year as well.
In an earlier interview with Baillargeon (http://ibn.fm/iAVOP), Wang
emphasized the bright future of the hemp/CBD industry in China, which has four
times the market potential of America. CBD Biotech is one of the first
companies to enter the industry, solidifying its place as a big player in the
future of cannabis in China.
Last year was a successful year for CIIX, and Wang is looking
forward to continued profitability and successful in 2020 as the company works
toward an even more stable future.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates
relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
